Our study showed that GnRHa treatment applied before myeloablative chemotherapy may be able to reduce the FSH level of patients after HSCT, but it still reaches the standard of POF; this finding revealed that GnRHa cannot reduce the incidence of premature ovarian failure in patients receiving myeloablative chemotherapy HSCT. The gene discussed is BRD2; the disease is primary ovarian failure.